Dollar Tree, Myriad Genetics and Antero face valuation concerns despite Wall Street upside targets

Analysts’ consensus price targets imply gains of more than 20% for Dollar Tree (NASDAQ: DLTR), Myriad Genetics (NASDAQ: MYGN) and Antero Resources (NYSE: AR), but StockStory said investors should weigh potential risks behind the bullish forecasts. Dollar Tree traded at $90.01, with a consensus target of $124.70, implying 38.5% upside, and was valued at 14 times forward earnings. Myriad Genetics traded at $4.26, with a $6.25 target implying 46.9% upside, while carrying a 32.9 times forward P/E multiple. Antero Resources traded at $36.67, with a $50.19 target implying 36.9% upside and an 8.2 times forward P/E. The commentary cautioned that sell-side analyst targets may be influenced by broader investment banking relationships and urged investors to compare the companies’ fundamentals before relying on upside projections.